WallStSmart
PRGO

Perrigo Company PLC

NYSE: PRGO · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC

$11.29
-1.91% today

Updated 2026-04-29

Market cap
$1.55B
P/E ratio
P/S ratio
0.37x
EPS (TTM)
$-10.12
Dividend yield
10.10%
52W range
$9 – $27
Volume
3.5M

Perrigo Company PLC (PRGO) Stock Valuation Analysis

Fair value estimate, historical valuation range, and quality signals for PRGO.

WallStSmart Verdict
Overvalued

Current price exceeds what fundamentals support. Risk/reward skewed unfavorably.

Smart Value Score: 48 / 100
P/E (TTM)
Not meaningful for this profile
PEG
1.14
Fair range
Margin of Safety
+82.18%
Fair value $81.94 vs $11.29
EV / EBITDA
0.0x

PRGO historical valuation range

Where current P/E sits in PRGO's own 5Y range.

Insufficient historical data for 5Y percentile analysis

PRGO intrinsic value (DCF)

DCF-based fair value estimate vs current market price.

Current price
$11.29
Market value
Intrinsic value
$81.94
DCF estimate
Margin of safety
+82.18%
+625.8% upside to fair value

Intrinsic value calculated using discounted cash flow (DCF) model based on projected free cash flows, discount rate, and terminal growth assumptions. A positive margin of safety indicates the current price is below estimated fair value, providing a cushion against estimation error.

PRGO valuation signals

Quick-read green flags, caution flags, and risks based on current metrics.

!
PEG in fair range
PEG of 1.14 suggests price reflects growth fairly. Neither a bargain nor overpriced.
Strong margin of safety
Current price 82.2% below DCF intrinsic value estimate. Meaningful downside cushion.

P/E Ratio — History

No historical P/E data available

P/S Ratio — History

Current: 0.36x

Is PRGO overvalued in 2026?

Perrigo Company PLC (PRGO) currently trades at $11.29 per share with a market capitalization of $1,554,061,000.00. Based on our multi-factor framework, the stock appears richly valued with a Smart Value Score of 48/100. This score blends growth quality, financial health, and price attractiveness into a single institutional-grade read.

PRGO currently has no meaningful P/E ratio, which typically signals that the company is unprofitable, near breakeven, or emerging from a loss-making period. With a P/S ratio of 0.4x, the market is valuing the company primarily on its revenue rather than its earnings.

Our discounted cash flow model estimates PRGO's intrinsic value at $81.94 per share, against the current market price of $11.29. This implies a margin of safety of +82.18%. A meaningful cushion exists against model error, making this a reasonable risk-adjusted entry.

The Piotroski F-Score of 4/9 puts financial quality in a middling range, neither a standout strength nor an obvious red flag.

Bottom line: PRGO appears richly valued on our framework, with a Smart Value Score of 48/100. At current levels the risk/reward is skewed against the buyer. A materially lower price or significant operational improvement would be needed to change the picture.

Frequently asked questions

Is PRGO overvalued in 2026?

Based on a Smart Value Score of 48/100, PRGO appears overvalued. Current price exceeds what fundamentals currently justify.

What is PRGO's fair value?

Our DCF model estimates PRGO's intrinsic value at $81.94 per share, versus the current price of $11.29. This produces a margin of safety of +82.18%.

What P/E ratio does PRGO trade at?

PRGO does not have a meaningful P/E ratio at this time, typically a sign of unprofitability or an ongoing earnings transition.

Is PRGO a buy based on valuation?

WallStSmart does not issue buy or sell recommendations. Our Smart Value Score of 48/100 reflects the combined read on growth, quality, and price. The profile skews cautious. Consider waiting for a better price or clearer operational improvement.

How does PRGO's valuation compare to its history?

Insufficient historical valuation data exists yet for a confident percentile read on PRGO.

What is PRGO's Smart Value Score?

PRGO's Smart Value Score is 48/100. The Smart Value Score is a proprietary WallStSmart metric blending growth quality, financial health, and valuation attractiveness into a single 0-100 read. Scores above 75 are rare and indicate strong multi-factor alignment.